Influence of Baseline Itch Severity on Treatment Outcomes With Difelikefalin in Adults With Moderate‐to‐Severe Pruritus Receiving Maintenance Haemodialysis: An Exploratory Analysis
Difelikefalin was well-tolerated and effective in reducing itch in participants with moderate and severe baseline itch, supporting its broad use in a range of individuals on HD with CKD-aP.
Authors
- Thilo Schaufler (ORCID: https://orcid.org/0000-0003-1886-829X)
- Daniel E. Weiner (ORCID: https://orcid.org/0000-0002-8775-394X)
- Kieran McCafferty (ORCID: https://orcid.org/0000-0002-0762-2270)
- Pablo Molina (ORCID: https://orcid.org/0000-0002-8311-6214)
- Warren Wen
- Murray Lowe
Institutions
- Tufts Medical Center (US)
- Universitat de València (ES)
- Barts Health NHS Trust (GB)
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (ES)
- Vifor Pharma (Switzerland) (CH)
- Hospital Universitario Doctor Peset (ES)
- Cara Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of Renal Care
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1111/jorc.70017
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Society of Nephrology
- Fresenius Medical Care North America